Conbercept is endowed with a stronger affinity for VEGF-A than other anti-VEGF agents and can effectively treat exudative AMD (15, 16); its therapeutic efficacy has been shown to vary among PCV patients. Here, VEGFA is linked to age-related macular degeneration.